Featured
Senolytic Combination Therapy (Dasatinib and Quercetin) Halts Progression of Idiopathic Pulmonary Fibrosis in Phase 2 Trial
A Phase 2 trial at MD Anderson demonstrates that the senolytic combination dasatinib and quercetin (D+Q) significantly slows lung function decline in ...
Read Full Story →